Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (1869)	10/22/2000 8:11:49 PM
From: scaram(o)uche	Respond to of 52153

SMH: Hey, I forgot to thank you for posting it. Didn't mean to imply that it shouldn't have been posted. Was glad for the pointer and disappointed that the article didn't have more meat to it. I wasn't saying "let's not discuss it further". I was asking "what's to discuss?" Didn't come across that way, sorry. I'll switch to being "short" -- for certain biotechs and at the appropriate time -- no sweat. I think that most of us will agree that the intent here is to make wise investments, not be a "rah rah" team for biotech. Was glad to see others slashing and bashing, however, and didn't mean to criticize it. Love this thread, and the new(er) contributors are doing great. Within the last very few days I read a comment (somewhere?) pointing out the legions of followers the Fools have. Point well-taken. We can all remember recent days when von Emster was shorting in the Franklin Fund. Never can tell when Jeff's lame brain dogma may catch on. I watch the two Fool principals when they appear on CNBC with their funny hats. They advise people to invest cautiously. This is a good thing. However, I've been assuming that an investment banker from MSDW should be serving time for this...... Message 13011487 Now you're telling me that it should be a Fool? Lots of overlap, I guess. will surely mark the beginning of the end. It's been sensational. So many cyberfriends, working together. We've got a nice crew, and WSJ would certainly notice that it's the Harmon-exclusive portfolios that have performed the worst, relative to the team effort portfolios. Cheers! Rick